Guidelines Development Group

The objective of the Guidelines Development Group (GDG) is to develop evidence-based European Guidelines for breast cancer screening and diagnosis (the European Breast Guidelines) for screening and diagnosis.

The GDG will follow the GRADE approach in defining the healthcare question of interest (population of interest, interventions to be compared and patient-relevant outcomes- PICO), synthesizing the evidence and developing the recommendations for the Guidelines. This will be carried out within virtual working environments and in meetings organised every three months. The initial draft documents and the final versions before publication are subject of open calls for feedback launched online.

The members are also invited to contribute to the other ECIBC objectives, the Digital Mammography Training Template and the European Guidelines Platform covering all processes of care (from screening to end-of-life care). 

An external contractor, CCIb –Iberoamerican Cochrane Centre, supports the GDG for their tasks from literature review to drafting of recommendations.

Privacy statement

Members and external experts

Back

Mariangela Autelitano

Mariangela Autelitano

My name is Mariangela Autelitano.

I am a medical doctor and also hold a Master's degree in epidemiology (LSHTM), a specialization degree in Hygiene and Public Health (University of Rome), and a Doctorate in Public Health (University of Milan).

Between 1994 and 1999 I worked as a doctor in the Milan airport’s health service, Linate and Malpensa airports.

Since 1999 I have been working in the epidemiology service of the Local Health Authority in Milan. I started organizing and directing the Milan mortality registry; in 2012, time at which I also became director of the Cancer Registry of Milan. I’m mainly involved in mortality and cancer, although my department gives epidemiological support to many activities for the local health service.

I participate in ECIBC as a patients-representative; I was diagnosed with breast cancer in February 2011. It was classified as an interval cancer (false negative), as I had undergone routine screening a few months before the diagnosis.

Declaration of interests



Last update: 2018